Understanding evaluation and management of primary cutaneous and systemic ALCL.
Vose
Julie M
JM
Division of Hematology/Oncology, University of Nebraska Medical Center, Omaha, Nebraska, USA.
D000077548:Anaplastic Lymphoma Kinase; D006801:Humans; D017730:Ki-1 Antigen; D017728:Lymphoma, Large-Cell, Anaplastic / Q000201:enzymology / Q000473:pathology* / Q000628:therapy*; D054446:Lymphoma, Primary Cutaneous Anaplastic Large Cell / Q000201:enzymology / Q000473:pathology* / Q000628:therapy*; D011505:Protein-Tyrosine Kinases / Q000378:metabolism; D020794:Receptor Protein-Tyrosine Kinases; D012878:Skin Neoplasms / Q000201:enzymology / Q000473:pathology* / Q000628:therapy*
D017730:Ki-1 Antigen; D000077548:Anaplastic Lymphoma Kinase; D011505:Protein-Tyrosine Kinases; D020794:Receptor Protein-Tyrosine Kinases